Genetic testing reduces adverse drug reactions by nearly a third, major trial results confirm The 'PREPARE' trial has demonstrated that genetic testing can significantly reduce adverse drug reactions, with the study coordinator stating there is enough evidence to "proceed with implementation".…
Making the case for pharmacogenomics in the management of mental health conditions A review of the management of mental health conditions and the role of genetics, along with the implementation of pharmacogenomic testing.…
Newborn genome screening: a step too far? A project to screen the genomes of 100,000 babies for rare diseases is set to begin recruiting in 2023, but it will face ethical and societal challenges.…
Should we be genetic testing before prescribing analgesics? Managing pain is difficult because there are various factors that can influence how it is perceived, but pharmacogenomic testing may be able to help fine tune pharmaceutical interventions.…
Pharmacists should be able to refer patients to NHS genomics services, says Royal Pharmaceutical Society In the Society's consultation response, Thorrun Govind said there needs to be an explanation of how pharmacy staff can enrich and complement the NHS Clinical Genomics Service.…
Adverse drug reactions reduced by nearly one third after genetic testing, major trial results to show Exclusive: Ahead of publication of the PREPARE study, the UK trial lead said the results will be "fantastic" news.…
UK adults asked to sign up to ‘exciting’ genomics study Data will be used to develop and test genetic risk scores for potential screening programmes, as well as earlier detection and targeted treatment of certain conditions.…
Drug-gene interaction testing may be about to go mainstream Ambitious plans for pre-emptive pharmacogenomic testing were put on hold during the COVID-19 pandemic, but NHS pilots next year could pave the way for major change.…
GPs to start genetic testing patients before prescribing statins, antidepressants and PPIs Exclusive: First-ever NHS pilot of routine genetic testing to guide drug choice in primary care will begin in early 2023 in north-west England, with plans for it to become a national programme if successful.…
The role of circulating tumour DNA in guiding cancer treatment and future applications An overview of current and future applications of circulating tumour DNA in common solid tumours and the implications on treatment.…
